270 related articles for article (PubMed ID: 35811461)
1. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies.
Ollila TA; Masel RH; Reagan JL; Lu S; Rogers RD; Paiva KJ; Taher R; Burguera-Couce E; Zayac AS; Yakirevich I; Niroula R; Barth P; Olszewski AJ
Cancer; 2022 Sep; 128(18):3319-3329. PubMed ID: 35811461
[TBL] [Abstract][Full Text] [Related]
2. Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders.
Ammitzbøll C; Kragh Thomsen M; Bøgh Andersen J; Jensen JMB; From Hermansen ML; Dahl Johannsen A; Larsen ML; Mistegaard CE; Mikkelsen S; Szabados F; Vils SR; Erikstrup C; Hauge EM; Troldborg A
Rheumatology (Oxford); 2023 Jul; 62(7):2544-2549. PubMed ID: 36445008
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario.
Krekeler C; Reitnauer L; Bacher U; Khandanpour C; Steger L; Boeckel GR; Klosner J; Tepasse PR; Kemper M; Hennies MT; Mesters R; Stelljes M; Schmitz N; Kerkhoff A; Schliemann C; Mikesch JH; Schmidt N; Lenz G; Bleckmann A; Shumilov E
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428605
[TBL] [Abstract][Full Text] [Related]
4. Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms.
Kobayashi M; Mori A; Onozawa M; Tsukamoto S; Senjo H; Ishio T; Yokoyama E; Kanaya M; Izumiyama K; Saito M; Muraki H; Morioka M; Teshima T; Kondo T
Ann Hematol; 2023 Apr; 102(4):819-827. PubMed ID: 36862167
[TBL] [Abstract][Full Text] [Related]
5. Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies.
Chung DJ; Shah GL; Devlin SM; Ramanathan LV; Doddi S; Pessin MS; Hoover E; Marcello LT; Young JC; Boutemine SR; Serrano E; Sharan S; Momotaj S; Margetich L; Bravo CD; Papanicolaou GA; Kamboj M; Mato AR; Roeker LE; Hultcrantz M; Mailankody S; Lesokhin AM; Vardhana SA; Knorr DA
Blood Cancer Discov; 2021 Nov; 2(6):568-576. PubMed ID: 34778797
[TBL] [Abstract][Full Text] [Related]
6. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.
Marchesi F; Salmanton-García J; Buquicchio C; Itri F; Besson C; Dávila-Valls J; Martín-Pérez S; Fianchi L; Rahimli L; Tarantini G; Grifoni FI; Sciume M; Labrador J; Cordoba R; López-García A; Fracchiolla NS; Farina F; Ammatuna E; Cingolani A; García-Bordallo D; Gräfe SK; Bilgin YM; Dargenio M; González-López TJ; Guidetti A; Lahmer T; Lavilla-Rubira E; Méndez GA; Prezioso L; Schönlein M; Van Doesum J; Wolf D; Hersby DS; Magyari F; Van Praet J; Petzer V; Tascini C; Falces-Romero I; Glenthøj A; Cornely OA; Pagano L
J Hematol Oncol; 2023 Apr; 16(1):32. PubMed ID: 37005697
[TBL] [Abstract][Full Text] [Related]
7. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
Guven DC; Sahin TK; Akın S; Uckun FM
Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.
Uaprasert N; Pitakkitnukun P; Tangcheewinsirikul N; Chiasakul T; Rojnuckarin P
Blood Cancer J; 2022 Dec; 12(12):173. PubMed ID: 36550105
[TBL] [Abstract][Full Text] [Related]
9. Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies.
Huang CT; Lee CP; Chen TY; Liu YC; Cho SF; Du JS; Yu ML; Huang CF; Wang SF; Hsiao HH
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685720
[TBL] [Abstract][Full Text] [Related]
10. A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies.
Owen C; Robinson S; Christofides A; Sehn LH
Curr Oncol; 2022 May; 29(6):3940-3949. PubMed ID: 35735424
[TBL] [Abstract][Full Text] [Related]
11. Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?
Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
Clin Exp Immunol; 2022 May; 207(3):263-271. PubMed ID: 35553629
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies.
Reimann P; Petzer V; Mündlein A; Hartmann B; Severgnini L; Winkler A; Lang T; Huynh M; Gasser K; Rüger J; Atzl M; Mink S; Fraunberger P; Schmidt S; Steiner N; Griesmacher A; Gunsilius E; Nachbaur D; Willenbacher W; Wolf D; Winder T; Benda MA
Ann Hematol; 2024 Jun; 103(6):2123-2131. PubMed ID: 38436671
[TBL] [Abstract][Full Text] [Related]
13. Booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies.
Mori A; Onozawa M; Kobayashi M; Tsukamoto S; Senjo H; Ishio T; Yokoyama E; Kanaya M; Izumiyama K; Saito M; Muraki H; Morioka M; Teshima T; Kondo T
Cancer Med; 2023 Aug; 12(16):16881-16888. PubMed ID: 37409608
[TBL] [Abstract][Full Text] [Related]
14. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study.
Demel I; Skopal D; Šafránková E; Rozsívalová P; Jindra P; Šrámek J; Turková A; Vydra J; Labská K; Vedrová J; Čerňan M; Szotkowski T; Móciková H; Hynková L; Šušol O; Kováčová I; Belada D; Hájek R
Ann Hematol; 2024 Mar; 103(3):981-992. PubMed ID: 38092996
[TBL] [Abstract][Full Text] [Related]
16. [Results of Booster Vaccination in Children with Primary Vaccine Failure after Initial Varicella Vaccination].
Ozakiv T; Nishimura N; Gotoh K; Funahashi K; Yoshii H; Okuno Y
Kansenshogaku Zasshi; 2016 May; 90(3):291-6. PubMed ID: 27529963
[TBL] [Abstract][Full Text] [Related]
17. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
Bonelli M; Mrak D; Tobudic S; Sieghart D; Koblischke M; Mandl P; Kornek B; Simader E; Radner H; Perkmann T; Haslacher H; Mayer M; Hofer P; Redlich K; Husar-Memmer E; Fritsch-Stork R; Thalhammer R; Stiasny K; Winkler S; Smolen JS; Aberle JH; Zeitlinger M; Heinz LX; Aletaha D
Ann Rheum Dis; 2022 May; 81(5):687-694. PubMed ID: 35027397
[TBL] [Abstract][Full Text] [Related]
18. Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy.
Cohen D; Hazut Krauthammer S; Cohen YC; Perry C; Avivi I; Herishanu Y; Even-Sapir E
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3540-3549. PubMed ID: 33966088
[TBL] [Abstract][Full Text] [Related]
19. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.
Corti C; Antonarelli G; Scotté F; Spano JP; Barrière J; Michot JM; André F; Curigliano G
Ann Oncol; 2022 Feb; 33(2):158-168. PubMed ID: 34718117
[TBL] [Abstract][Full Text] [Related]
20. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
